打开APP

柳暗花明,阿斯利康抗凝血药Brilinta新适应症发现

  1. Brilinta
  2. 抗凝血
  3. 新适应症
  4. 阿斯利康

来源:生物谷 2015-01-16 09:25

近日一项临床试验表明,阿斯利康的抗凝血药Brilinta能降低心脏病患者的发病死亡风险,这将会为Brilinta带来新的应用前景。

柳暗花明,阿斯利康抗凝血药Brilinta新适应症发现

2015年1月16日讯/生物谷BIOON/--近日一项临床试验表明,阿斯利康的抗凝血药Brilinta能降低心脏病患者的发病死亡风险,这将会为Brilinta带来新的应用前景。

若今后给具有一年以上心脏病史的患者开具Brilinta处方,则处方量会是原有适应症的两倍之多,这将会极大地促进Brilinta的销量,预计将会给阿斯利康带来每年35亿美元的销售额。

这项名为PEGASUS的临床试验的受试者为21000名患者,这些患者在过去的一到三年中都罹患过心脏病,这项试验旨在证明Brilinta治疗急性冠脉综合征的价值超过目前市面上所有获批的同类药物。

Brilinta目前在抗凝药市场上的竞争力已经不足,原因主要是赛诺菲和百时美联合研发的仿制药Plavix具有更明显的价格优势,同时Brilinta还要面临与礼来的Effient之间的竞争。

由于阿斯利康去年拒绝了辉瑞1180亿美元的收购意向,阿斯利康的董事长Pascal Soriot如今把Brilinta作为销售重点,预计到2023年之前每年能为阿斯利康贡献35亿美元的销售额,这对于阿斯利康实现2023年总销售额450亿美元的目标至关重要,尽管目前有些分析师对此呈怀疑态度。

2014年前九个月中Brilinta的销售额是3.43亿美元,基本可以实现2019年12.3亿美元销售额的目标。阿斯利康的相关负责人表示,他们希望2015年Brilinta的销售额能够进一步增长,而这次临床试验的阳性结果无疑能够起到推动作用。

业内的分析师认为,该试验结果确实对阿斯利康是极大地助力,但是希望能够看到试验更多的细节,尤其是关于出血方面的数据,因为所有的抗凝血药物都会引发出血。

到目前为止,阿斯利康仅公布了一部分PEGASUS的数据,表明在同时服用阿司匹林的情况下,60mg和90mg剂量的Brilinta结果呈阳性,并且未发现安全性问题。

据悉,所有的试验结果将会在2015年的科学会议上公布。

为了进一步发现Brilinta的价值,阿斯利康正在研究其对中风、外周动脉疾病和糖尿病方面的作用。(生物谷Bioon.com)

原文 AstraZeneca heart drug boosted by major clinical trial success

AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

Giving Brilinta to patients who had a heart attack over a year ago could more than double the number of people eligible for the medicine, which the company has predicted could eventually generate sales of $3.5 billion a year.

Results from the 21,000-patient study, known as PEGASUS, were released on Wednesday, lifting shares in AstraZeneca 1.5 percent by 5:00 a.m. EST, while the wider London market fell one percent.

The trial, which studied subjects who had a heart attack within the past one to three years, was designed to prove Brilinta's value beyond its current approved use in patients with acute coronary syndromes, or recent attacks.

Brilinta has struggled so far to gain traction in a competitive market for blood thinners, where Plavix -- developed by Sanofi and Bristol-Myers Squibb -- is now available as a cheap generic. Brilinta also competes with Eli Lilly's Effient.

AstraZeneca Chief Executive Pascal Soriot has made Brilinta a top priority and the company flagged its potential when he fought off a $118 billion bid by Pfizer last year, forecasting annual sales of $3.5 billion for the drug by 2023.

That makes Brilinta a critical component in AstraZeneca's wider goal of reaching overall sales of $45 billion by 2023, although many analysts remain skeptical.

The drug's sales in the first nine months of 2014 were $343 million and consensus forecasts point to them hitting only $1.23 billion by 2019, according to Thomson Reuters Cortellis.

Tom Keith-Roach, vice president for Brilinta, told Reuters he expected sales to strengthen through 2015 and the latest positive trial results should lead to expanded approvals in major markets over the next 18 months.

"This is very important news for the franchise," he said.

Analysts agreed the study was a clear win for AstraZeneca but said they wanted to see full details on the magnitude of clinical benefit, as well as data on bleeding. All blood-thinning drugs can cause bleeds.

So far, AstraZeneca has only said that the PEGASUS data was positive for both the 60 mg and 90 mg doses of Brilinta, when given alongside low-dose aspirin, and that preliminary analysis did not reveal any unexpected safety issues.

Complete results from the study will be submitted to a scientific meeting in 2015.

AstraZeneca is also conducting further studies looking at Brilinta's use in stroke, peripheral artery disease and diabetes.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->